Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Monopar Therapeutics appoints Laura Kelly as director, clinical operations » 07:20
02/18/21
02/18
07:20
02/18/21
07:20
MNPR

Monopar Therapeutics

$9.23 /

-0.465 (-4.80%)

Monopar Therapeutics …

Monopar Therapeutics announced the appointment of Laura Kelly as Director of Clinical Operations. Ms. Kelly will be responsible for managing Monopar's clinical programs, including the recently launched Phase 2b/3 VOICE trial for the Company's lead drug candidate Validive. Prior to Monopar, Ms. Kelly served in strategic and clinical operation leadership roles at Merck/EMD Serono, AbbVie, Abbott Labs, and Amgen.

ShowHide Related Items >><<
MNPR Monopar Therapeutics
$9.23 /

-0.465 (-4.80%)

MNPR Monopar Therapeutics
$9.23 /

-0.465 (-4.80%)

01/28/21 Roth Capital
Monopar Therapeutics initiated with a Buy at Roth Capital
09/24/20 Maxim
Monopar Therapeutics initiated with a Buy at Maxim
06/16/20 JonesTrading
JonesTrading backs Buy on Monoper after NorthStar Medical collaboration
02/19/20 Brookline
Monopar Therapeutics initiated with a Buy at Brookline
MNPR Monopar Therapeutics
$9.23 /

-0.465 (-4.80%)

Over a week ago
Hot Stocks
Monopar Therapeutics doses first patient in Phase 2b/3 VOICE trial » 07:46
02/16/21
02/16
07:46
02/16/21
07:46
MNPR

Monopar Therapeutics

$10.02 /

-0.64 (-6.00%)

Monopar Therapeutics…

Monopar Therapeutics announced it has dosed the first patient in its Phase 2b/3 VOICE trial of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in patients with oropharyngeal cancer. Validive's mucoadhesive buccal tablet formulation allows for prolonged and enhanced local delivery of drug to the regions of mucosal radiation damage, and its easy application under the upper lip allows for convenient once-daily self-administration in the patient's home setting.

ShowHide Related Items >><<
MNPR Monopar Therapeutics
$10.02 /

-0.64 (-6.00%)

MNPR Monopar Therapeutics
$10.02 /

-0.64 (-6.00%)

01/28/21 Roth Capital
Monopar Therapeutics initiated with a Buy at Roth Capital
09/24/20 Maxim
Monopar Therapeutics initiated with a Buy at Maxim
06/16/20 JonesTrading
JonesTrading backs Buy on Monoper after NorthStar Medical collaboration
02/19/20 Brookline
Monopar Therapeutics initiated with a Buy at Brookline
MNPR Monopar Therapeutics
$10.02 /

-0.64 (-6.00%)

Hot Stocks
Monopar Therapeutics announces peer-reviewed study on MNPR-101 » 07:43
02/11/21
02/11
07:43
02/11/21
07:43
MNPR

Monopar Therapeutics

$8.46 /

-0.21 (-2.42%)

Monopar Therapeutics…

Monopar Therapeutics announced the publication of a peer-reviewed study in the European Journal of Cancer which shows the potential utility of MNPR-101 as a uPAR imaging agent to improve surgical outcomes in bladder cancer. Using Monopar's proprietary humanized uPAR antibody, MNPR-101, a multimodal imaging probe was developed and tested in vivo in human bladder cancer models. The publication reports that high expression of uPAR in bladder cancer is localized at the tumor periphery, suggesting that using a fluorescent-conjugated MNPR-101 probe might allow surgeons to better visualize the borders of the tumor, potentially resulting in more complete tumor resection and thereby minimizing relapse. Similar approaches have been utilized successfully in the resection of other tumor types, such as breast cancer.

ShowHide Related Items >><<
MNPR Monopar Therapeutics
$8.46 /

-0.21 (-2.42%)

MNPR Monopar Therapeutics
$8.46 /

-0.21 (-2.42%)

01/28/21 Roth Capital
Monopar Therapeutics initiated with a Buy at Roth Capital
09/24/20 Maxim
Monopar Therapeutics initiated with a Buy at Maxim
06/16/20 JonesTrading
JonesTrading backs Buy on Monoper after NorthStar Medical collaboration
02/19/20 Brookline
Monopar Therapeutics initiated with a Buy at Brookline
MNPR Monopar Therapeutics
$8.46 /

-0.21 (-2.42%)

Hot Stocks
Monopar Therapeutics issued Canadian patent covering MNPR-101 » 07:08
02/09/21
02/09
07:08
02/09/21
07:08
MNPR

Monopar Therapeutics

$8.34 /

+0.38 (+4.77%)

Monopar Therapeutics…

Monopar Therapeutics announced the issuance of a patent covering composition of matter for MNPR-101 in Canada, adding to its existing protection in key markets around the world including the US, Europe and Japan. In June 2020, Monopar entered into a collaboration with NorthStar Medical Radioisotopes to utilize MNPR-101 to create a radio-immuno-therapeutic to potentially treat severe COVID-19 by targeting and eradicating the aberrantly activated immune cells causing cytokine storm.

ShowHide Related Items >><<
MNPR Monopar Therapeutics
$8.34 /

+0.38 (+4.77%)

MNPR Monopar Therapeutics
$8.34 /

+0.38 (+4.77%)

01/28/21 Roth Capital
Monopar Therapeutics initiated with a Buy at Roth Capital
09/24/20 Maxim
Monopar Therapeutics initiated with a Buy at Maxim
06/16/20 JonesTrading
JonesTrading backs Buy on Monoper after NorthStar Medical collaboration
02/19/20 Brookline
Monopar Therapeutics initiated with a Buy at Brookline
MNPR Monopar Therapeutics
$8.34 /

+0.38 (+4.77%)

Initiation
Monopar Therapeutics initiated with a Buy at Roth Capital » 06:14
01/28/21
01/28
06:14
01/28/21
06:14
MNPR

Monopar Therapeutics

$6.60 /

-0.25 (-3.65%)

Roth Capital analyst…

Roth Capital analyst Elemer Piros initiated coverage of Monopar Therapeutics with a Buy rating and $49 price target. The company intends to fill the void created by a recent drug failure and market withdrawal in oral mucositis and soft tissue sarcoma, Piros tells investors in a research note. There are no drugs approved for severe oral mucositis, and Monopar and Galera are the only two companies with programs in advanced clinical trials, says the analyst.

ShowHide Related Items >><<
MNPR Monopar Therapeutics
$6.60 /

-0.25 (-3.65%)

MNPR Monopar Therapeutics
$6.60 /

-0.25 (-3.65%)

09/24/20 Maxim
Monopar Therapeutics initiated with a Buy at Maxim
06/16/20 JonesTrading
JonesTrading backs Buy on Monoper after NorthStar Medical collaboration
02/19/20 Brookline
Monopar Therapeutics initiated with a Buy at Brookline
02/03/20 JonesTrading
Monopar Therapeutics initiated with a Buy at JonesTrading
MNPR Monopar Therapeutics
$6.60 /

-0.25 (-3.65%)

Conference/Events
Monopar Therapeutics management to meet virtually with Roth Capital » 04:55
01/27/21
01/27
04:55
01/27/21
04:55
MNPR

Monopar Therapeutics

$6.85 /

-0.25 (-3.52%)

Virtual Meeting to be…

Virtual Meeting to be held on January 27 hosted by Roth Capital.

ShowHide Related Items >><<
MNPR Monopar Therapeutics
$6.85 /

-0.25 (-3.52%)

MNPR Monopar Therapeutics
$6.85 /

-0.25 (-3.52%)

09/24/20 Maxim
Monopar Therapeutics initiated with a Buy at Maxim
06/16/20 JonesTrading
JonesTrading backs Buy on Monoper after NorthStar Medical collaboration
02/19/20 Brookline
Monopar Therapeutics initiated with a Buy at Brookline
02/03/20 JonesTrading
Monopar Therapeutics initiated with a Buy at JonesTrading
MNPR Monopar Therapeutics
$6.85 /

-0.25 (-3.52%)

Conference/Events
Monopar Therapeutics management to meet virtually with Roth Capital » 12:44
01/26/21
01/26
12:44
01/26/21
12:44
MNPR

Monopar Therapeutics

$6.74 /

-0.36 (-5.07%)

Virtual Meeting to be…

Virtual Meeting to be held on January 27 hosted by Roth Capital.

ShowHide Related Items >><<
MNPR Monopar Therapeutics
$6.74 /

-0.36 (-5.07%)

MNPR Monopar Therapeutics
$6.74 /

-0.36 (-5.07%)

09/24/20 Maxim
Monopar Therapeutics initiated with a Buy at Maxim
06/16/20 JonesTrading
JonesTrading backs Buy on Monoper after NorthStar Medical collaboration
02/19/20 Brookline
Monopar Therapeutics initiated with a Buy at Brookline
02/03/20 JonesTrading
Monopar Therapeutics initiated with a Buy at JonesTrading
MNPR Monopar Therapeutics
$6.74 /

-0.36 (-5.07%)

Over a month ago
Hot Stocks
Monopar Therapeutics announces issuance of U.S. patent for camsirubicin analogs » 08:35
12/22/20
12/22
08:35
12/22/20
08:35
MNPR

Monopar Therapeutics

$5.67 /

-0.18 (-3.08%)

Monopar Therapeutics…

Monopar Therapeutics announced the issuance of a U.S. patent covering compositions of matter for a novel family of camsirubicin analogs. The patent, which expands the Company's camsirubicin intellectual property portfolio, is expected to expire in 2038 not including any patent term extensions. Doxorubicin is FDA approved in 14 different types of cancers including soft tissue and bone sarcomas; metastatic stomach, ovarian, thyroid, lung, and breast cancer; acute myeloid and lymphoblastic leukemia; Hodgkin and non-Hodgkin lymphoma; and neuroblastoma. However, cumulative dose effects of doxorubicin can result in irreversible heart damage and death, which is why a restrictive lifetime cumulative dose limitation has been placed on its use. Monopar's clinical trial collaboration partner, Grupo Espanol de Investigacion en Sarcomas, an internationally renowned non-profit organization focused on the research and development of drugs for sarcomas, is on track to initiate an open-label Phase 2 clinical study in early 2021 evaluating camsirubicin head-to-head against doxorubicin in advanced soft tissue sarcoma, where doxorubicin is currently the first-line treatment.

ShowHide Related Items >><<
MNPR Monopar Therapeutics
$5.67 /

-0.18 (-3.08%)

MNPR Monopar Therapeutics
$5.67 /

-0.18 (-3.08%)

09/24/20 Maxim
Monopar Therapeutics initiated with a Buy at Maxim
06/16/20 JonesTrading
JonesTrading backs Buy on Monoper after NorthStar Medical collaboration
02/19/20 Brookline
Monopar Therapeutics initiated with a Buy at Brookline
02/03/20 JonesTrading
Monopar Therapeutics initiated with a Buy at JonesTrading
MNPR Monopar Therapeutics
$5.67 /

-0.18 (-3.08%)

Hot Stocks
Monopar Therapeutics, NorthStar announce selection of uPRIT candidate » 08:41
12/10/20
12/10
08:41
12/10/20
08:41
MNPR

Monopar Therapeutics

$5.66 /

+0.52 (+10.12%)

Monopar Therapeutics and…

Monopar Therapeutics and NorthStar Medical Radioisotopes, which are jointly developing a urokinase plasminogen activator receptor targeted radio-immuno-therapeutic for the potential treatment of severe COVID-19, announced the selection of a uPRIT clinical candidate. Monopar and NorthStar partnered with IsoTherapeutics Group to generate a panel of uPRIT leads, which were then screened by Aragen Bioscience Inc., resulting in the identification of a uPRIT clinical candidate plus several backup candidates. uPRITs are analogs of MNPR-101, Monopar's proprietary humanized urokinase plasminogen activator receptor targeted antibody, that have been modified to enable attachment of a therapeutic radioisotope. uPRITs bind to uPAR with high affinity and are thought to selectively recognize the aberrantly activated, pro-inflammatory immune cells that express this target and also seem to be mediating the cytokine storm leading to respiratory failure and poor outcomes in severe COVID-19 patients. The cleaved, blood-circulating soluble form of uPAR, suPAR, has been gaining attention as a potentially important prognostic biomarker for severe COVID-19 in several recently published studies. Rovina et al. 2020 showed that patients with elevated levels of suPAR at the time of hospital admission are 17 times more likely to develop severe respiratory failure; Arnold et al. 2020 showed suPAR to have the best performance in predicting outcome of all the biomarkers examined; and Eugen-Olsen et al. 2020 showed that low levels of suPAR are predictive of mild outcome in COVID-19 patients. The aim with uPRITs is to bind to and rapidly eliminate the aberrantly activated immune cells, quickly shutting down the cytokine storm. If uPRITs are effective in this setting, they may also be effective in treating other diseases characterized by rapid and severe systemic inflammatory responses, including certain pneumonias and sepsis. The uPRIT with the most attractive uPAR binding profile was selected to advance into IND-enabling studies.

ShowHide Related Items >><<
MNPR Monopar Therapeutics
$5.66 /

+0.52 (+10.12%)

MNPR Monopar Therapeutics
$5.66 /

+0.52 (+10.12%)

09/24/20 Maxim
Monopar Therapeutics initiated with a Buy at Maxim
06/16/20 JonesTrading
JonesTrading backs Buy on Monoper after NorthStar Medical collaboration
02/19/20 Brookline
Monopar Therapeutics initiated with a Buy at Brookline
02/03/20 JonesTrading
Monopar Therapeutics initiated with a Buy at JonesTrading
MNPR Monopar Therapeutics
$5.66 /

+0.52 (+10.12%)

  • 19
    Dec
Hot Stocks
Monopar Therapeutics intiates Phase 2b/3 trial of Validive » 08:36
12/08/20
12/08
08:36
12/08/20
08:36
MNPR

Monopar Therapeutics

$4.76 /

-0.09 (-1.86%)

Monopar Therapeutics…

Monopar Therapeutics announced that its Phase 2b/3 clinical trial of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in patients with oropharyngeal cancer is active and recruiting patients. The completed Phase 2 trial showed the incidence of SOM in OPC patients receiving Validive 100 microgram to be 40% lower compared to those receiving placebo. It is estimated there will be greater than 40,000 new OPC patients in the U.S. alone in 2021, the majority of whom will be treated with chemoradiation and run substantial risk of developing SOM. Currently, there is no FDA approved preventive or treatment for SOM in these patients, emphasizing the clear unmet medical need in this patient population. Up to approximately 260 patients will be enrolled in this multi-center, randomized, double-blind, placebo-controlled, Phase 2b/3 clinical trial. The trial includes an interim analysis, which is anticipated to be reached approximately twelve months after the first patient is dosed.

ShowHide Related Items >><<
MNPR Monopar Therapeutics
$4.76 /

-0.09 (-1.86%)

MNPR Monopar Therapeutics
$4.76 /

-0.09 (-1.86%)

09/24/20 Maxim
Monopar Therapeutics initiated with a Buy at Maxim
06/16/20 JonesTrading
JonesTrading backs Buy on Monoper after NorthStar Medical collaboration
02/19/20 Brookline
Monopar Therapeutics initiated with a Buy at Brookline
02/03/20 JonesTrading
Monopar Therapeutics initiated with a Buy at JonesTrading
MNPR Monopar Therapeutics
$4.76 /

-0.09 (-1.86%)

  • 19
    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.